Difference between revisions of "Vortioxetine-paroxetine"

From Psychiatrienet
Jump to: navigation, search
Line 5: Line 5:
 
{{stopVortioxetine}}
 
{{stopVortioxetine}}
 
| start =  
 
| start =  
{{washout9-15}}
+
{{washout8-14}}
 
* '''Day 16:''' start administration of paroxetine in a normal dosage of 10-20 mg/day.
 
* '''Day 16:''' start administration of paroxetine in a normal dosage of 10-20 mg/day.
 
| info =  
 
| info =  
 
* {{theorSS}}
 
* {{theorSS}}
 
* Paroxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}
 
* Paroxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}

Revision as of 14:53, 4 November 2015

Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine

Switch medication from vortioxetine to paroxetine.

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 8: stop administration of vortioxetine.
Eenrichtingbord.png Start paroxetine
  • Day 8-14: a wash-out period of 1 week is necessary.
  • Day 16: start administration of paroxetine in a normal dosage of 10-20 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Paroxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.